Eyepoint Pharmaceuticals, INC Form 4 insider transactions

Nancy Lurker, Executive Vice Chair of EyePoint Pharmaceuticals, reports the vesting of restricted stock units and subsequent disposal of shares to cover taxes.

Karen L. Zaderej, a director at EyePoint Pharmaceuticals, exercised stock options and converted restricted stock units into common stock on July 11, 2024.

Director Anthony P. Adamis of EyePoint Pharmaceuticals reports the acquisition and disposal of common stock and restricted stock units on June 23, 2024.

David R. Guyer, a director at EyePoint Pharmaceuticals, exercised stock options and sold shares of common stock on June 3, 2024.

Chief Financial Officer of EyePoint Pharmaceuticals, George Elston, reports acquisition and disposal of company stock and restricted stock units.

David R. Guyer, a director at EyePoint Pharmaceuticals, exercised stock options and sold shares on May 14, 2024, according to a Form 4 filing with the SEC.

Cormorant Asset Management, LP, along with related entities, reports purchasing additional shares of EyePoint Pharmaceuticals, Inc. common stock.

Cormorant Asset Management, LP, along with related entities and Bihua Chen, reported purchasing additional shares of EyePoint Pharmaceuticals, Inc. on April 18, 2024, increasing their beneficial ownership.

Dario A. Paggiarino, Chief Medical Officer of EyePoint Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units to satisfy tax obligations.

EyePoint Pharmaceuticals' Chief Medical Officer, Ramiro Ribeiro, reports the acquisition of stock options.

Jay S. Duker, President and CEO of EyePoint Pharmaceuticals, transferred 2,500 shares of common stock to a family trust on February 27, 2024.